1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Parasites

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: Elitza S. Theel1, Bobbi S. Pritt2
  • Editors: Randall T. Hayden3, Donna M. Wolk4, Karen C. Carroll5, Yi-Wei Tang6
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Mayo Clinic, Rochester, MN 55905; 2: Mayo Clinic, Rochester, MN 55905; 3: St. Jude’s Children’s Research Hospital, Memphis, TN; 4: Geisinger Clinic, Danville, PA; 5: Johns Hopkins University Hospital, Baltimore, MD; 6: Memorial Sloan-Kettering Institute, New York, NY
  • Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
  • Received 18 May 2015 Accepted 03 February 2016 Published 12 August 2016
  • Bobbi S. Pritt, Pritt.bobbi@mayo.edu
image of Parasites
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Parasites, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/4/4/DMIH2-0013-2015-1.gif /docserver/preview/fulltext/microbiolspec/4/4/DMIH2-0013-2015-2.gif
  • Abstract:

    Parasites are an important cause of human disease worldwide. The clinical severity and outcome of parasitic disease is often dependent on the immune status of the host. Specific parasitic diseases discussed in this chapter are amebiasis, giardiasis, cryptosporidiosis, cyclosporiasis, cystoisosporiasis, microsporidosis, granulomatous amebic encephalitis, toxoplasmosis, leishmaniasis, Chagas disease, malaria, babesiosis, strongyloidiasis, and scabies.

  • Citation: Theel E, Pritt B. 2016. Parasites. Microbiol Spectrum 4(4):DMIH2-0013-2015. doi:10.1128/microbiolspec.DMIH2-0013-2015.

Key Concept Ranking

Parasitic Life Cycle
0.5319547
Infection and Immunity
0.43707573
Acute Respiratory Distress Syndrome
0.4339717
Luciferase Immunoprecipitation Systems Assay
0.40736398
0.5319547

References

1. World Health Organization. 2014. World malaria report 2014. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2010. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. World Health Organization, Geneva, Switzerland.
3. Evering T, Weiss LM. 2006. The immunology of parasite infections in immunocompromised hosts. Parasite Immunol 28:549–565. [CrossRef]
4. MacDonald AS, Araujo MI, Pearce EJ. 2002. Immunology of parasitic helminth infections. Infect Immun 70:427–433. [PubMed][CrossRef]
5. Cooper PJ. 2009. Mucosal immunology of geohelminth infections in humans. Mucosal Immunol 2:288–299. [PubMed][CrossRef]
6. Stark D, Barratt JL, van Hal S, Marriott D, Harkness J, Ellis JT. 2009. Clinical significance of enteric protozoa in the immunosuppressed human population. Clin Microbiol Rev 22:634–650. [PubMed][CrossRef]
7. Ferreira MS. 2000. Infections by protozoa in immunocompromised hosts. Mem Inst Oswaldo Cruz 95(Suppl 1):159–162. [PubMed][CrossRef]
8. Pavie J, Menotti J, Porcher R, Donay JL, Gallien S, Sarfati C, Derouin F, Molina JM. 2012. Prevalence of opportunistic intestinal parasitic infections among HIV-infected patients with low CD4 cells counts in France in the combination antiretroviral therapy era. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 16:e677–679.
9. Marcos LA, Gotuzzo E. 2013. Intestinal protozoan infections in the immunocompromised host. Curr Opin Infect Dis 26:295–301. [CrossRef]
10. Stark D, Fotedar R, van Hal S, Beebe N, Marriott D, Ellis JT, Harkness J. 2007. Prevalence of enteric protozoa in human immunodeficiency virus (HIV)-positive and HIV-negative men who have sex with men from Sydney, Australia. Am J Trop Med Hyg 76:549–552. [PubMed]
11. Pritt BS, Clark CG. 2008. Amebiasis. Mayo Clin Proc 83:1154–1160, quiz 1159–1160. [PubMed][CrossRef]
12. Gathiram V, Jackson TF. 1985. Frequency distribution of Entamoeba histolytica zymodemes in a rural South African population. Lancet 1:719–721. [CrossRef]
13. Haque R, Ali IM, Petri WA Jr. 1999. Prevalence and immune response to Entamoeba histolytica infection in preschool children in Bangladesh. Am J Trop Med Hyg 60:1031–1034. [PubMed]
14. Solaymani-Mohammadi S, Rezaian M, Babaei Z, Rajabpour A, Meamar AR, Pourbabai AA, Petri WA Jr. 2006. Comparison of a stool antigen detection kit and PCR for diagnosis of Entamoeba histolytica and Entamoeba dispar infections in asymptomatic cyst passers in Iran. J Clin Microbiol 44:2258–2261. [PubMed][CrossRef]
15. Huston CD, Petri WA. 1999. Amebiasis: clinical implications of the recognition of Entamoeba dispar. Curr Infect Dis Rep 1:441–447. [PubMed][CrossRef]
16. Anonymous. 1997. WHO/PAHO/UNESCO report. A consultation with experts on amoebiasis. Mexico City, Mexico 28-29 January, 1997. Epidemiol Bull 18:13–14.
17. Law CL, Walker J, Qassim MH. 1991. Factors associated with the detection of Entamoeba histolytica in homosexual men. Int J STD AIDS 2:346–350. [PubMed]
18. Stanley SL Jr. 2003. Amoebiasis. Lancet 361:1025–1034. [PubMed][CrossRef]
19. Ali IK, Mondal U, Roy S, Haque R, Petri WA Jr, Clark CG. 2007. Evidence for a link between parasite genotype and outcome of infection with Entamoeba histolytica. J Clin Microbiol 45:285–289. [PubMed][CrossRef]
20. Moonah SN, Jiang NM, Petri WA Jr. 2013. Host immune response to intestinal amebiasis. PLoS Pathog 9:e1003489. [PubMed][CrossRef]
21. Frederick JR, Petri WA Jr. 2005. Roles for the galactose-/N-acetylgalactosamine-binding lectin of Entamoeba in parasite virulence and differentiation. Glycobiology 15:53R–59R. [PubMed][CrossRef]
22. Ackers JP, Mirelman D. 2006. Progress in research on Entamoeba histolytica pathogenesis. Curr Opin Microbiol 9:367–373. [PubMed][CrossRef]
23. Santi-Rocca J, Rigothier MC, Guillén N. 2009. Host-microbe interactions and defense mechanisms in the development of amoebic liver abscesses. Clin Microbiol Rev 22:65–75. [PubMed][CrossRef]
24. el-Hennawy M, Abd-Rabbo H. 1978. Hazards of cortisone therapy in hepatic amoebiasis. J Trop Med Hyg 81:71–73. [PubMed]
25. Denis M, Chadee K. 1988. Immunopathology of Entamoeba histolytica infections. Parasitol Today 4:247–252. [PubMed][CrossRef]
26. Morán P, Ramos F, Ramiro M, Curiel O, González E, Valadez A, Gómez A, García G, Melendro EI, Ximénez C. 2005. Infection by human immunodeficiency virus-1 is not a risk factor for amebiasis. Am J Trop Med Hyg 73:296–300. [PubMed]
27. Chen Y, Zhang Y, Yang B, Qi T, Lu H, Cheng X, Tachibana H. 2007. Seroprevalence of Entamoeba histolytica infection in HIV-infected patients in China. Am J Trop Med Hyg 77:825–828. [PubMed]
28. Tsai JJ, Sun HY, Ke LY, Tsai KS, Chang SY, Hsieh SM, Hsiao CF, Yen JH, Hung CC, Chang SC. 2006. Higher seroprevalence of Entamoeba histolytica infection is associated with human immunodeficiency virus type 1 infection in Taiwan. Am J Trop Med Hyg 74:1016–1019. [PubMed]
29. Hung CC, Deng HY, Hsiao WH, Hsieh SM, Hsiao CF, Chen MY, Chang SC, Su KE. 2005. Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan. Arch Intern Med 165:409–415. [PubMed][CrossRef]
30. Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, Kim NJ, Oh MD, Choe KW. 2007. Amebic liver abscess in HIV-infected patients, Republic of Korea. Emerg Infect Dis 13:516–517. [PubMed][CrossRef]
31. Garcia LS. 2007. Diagnostic Medical Parasitology, 5th ed. ASM Press, Washington, DC.
32. Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. 2007. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 20:511–532. [PubMed][CrossRef]
33. Vasoo S, Pritt BS. 2013. Molecular diagnostics and parasitic disease. Clin Lab Med 33:461–503. [PubMed][CrossRef]
34. Medical Letter Inc. 2013. Drugs for Parasitic Infections, 3rd ed, vol 11. The Medical Letter, New Rochelle, NY.
35. Garcia LS. 2007. Diagnostic Medical Parasitology, 5th ed. ASM Press, Washington, DC.
36. Centers for Disease Control and Prevention. 2011. Parasites - Giardia. [Online.]
37. Painter JE, Gargano JW, Collier SA, Yoder JS, Centers for Disease Control and Prevention. 2015. Giardiasis surveillance—United States, 2011-2012. MMWR Surveill Summ 64(Suppl 3):15–25.
38. Noureldin MS, Shaltout AA, El Hamshary EM, Ali ME. 1999. Opportunistic intestinal protozoal infections in immunocompromised children. J Egypt Soc Parasitol 29:951–961. [PubMed]
39. Smith PD, Lane HC, Gill VJ, Manischewitz JF, Quinnan GV, Fauci AS, Masur H. 1988. Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann Intern Med 108:328–333. [PubMed][CrossRef]
40. Faubert G. 2000. Immune response to Giardia duodenalis. Clin Microbiol Rev 13:35–54. [PubMed][CrossRef]
41. Johnston SP, Ballard MM, Beach MJ, Causer L, Wilkins PP. 2003. Evaluation of three commercial assays for detection of Giardia and Cryptosporidium organisms in fecal specimens. J Clin Microbiol 41:623–626. [PubMed][CrossRef]
42. Arisue N, Hashimoto T. 2014. Phylogeny and evolution of apicoplasts and apicomplexan parasites. Parasitol Int 64:254–259. [PubMed][CrossRef]
43. Barta JR, Thompson RC. 2006. What is Cryptosporidium? Reappraising its biology and phylogenetic affinities. Trends Parasitol 22:463–468. [PubMed][CrossRef]
44. Centers for Disease Control and Prevention. 2015. Parasites - Cryptosporidium. Centers for Disease Control and Prevention.
45. Mac Kenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE, Kazmierczak JJ, Addiss DG, Fox KR, Rose JB, Davis JP. 1994. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N Engl J Med 331:161–167. [PubMed][CrossRef]
46. Naumova EN, Egorov AI, Morris RD, Griffiths JK. 2003. The elderly and waterborne Cryptosporidium infection: gastroenteritis hospitalizations before and during the 1993 Milwaukee outbreak. Emerg Infect Dis 9:418–425. [PubMed][CrossRef]
47. Hoxie NJ, Davis JP, Vergeront JM, Nashold RD, Blair KA. 1997. Cryptosporidiosis-associated mortality following a massive waterborne outbreak in Milwaukee, Wisconsin. Am J Public Health 87:2032–2035. [PubMed][CrossRef]
48. Centers for Disease Control and Prevention. 2015. Parasites - Cyclosporiasis (Cyclospora Infection). Centers for Disease Control and Prevention.
49. Bern C. 2011. Antitrypanosomal therapy for chronic Chagas’ disease. N Engl J Med 364:2527–2534. [PubMed][CrossRef]
50. Guiguet M, Furco A, Tattevin P, Costagliola D, Molina JM, French Hospital Database on HIV Clinical Epidemiology Group. 2007. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV. HIV Med 8:124–130. [PubMed][CrossRef]
51. Cello JP. 1989. Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease. Am J Med 86:539–546. [PubMed][CrossRef]
52. Hunter PR, Nichols G. 2002. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev 15:145–154. [CrossRef]
53. Zar FA, El-Bayoumi E, Yungbluth MM. 2001. Histologic proof of acalculous cholecystitis due to Cyclospora cayetanensis. Clin Infect Dis 33:E140–E141. [PubMed][CrossRef]
54. Di Gliullo AB, Cribari MS, Bava AJ, Cicconetti JS, Collazos R. 2000. Cyclospora cayetanensis in sputum and stool samples. Rev Inst Med Trop Sao Paulo 42:115–117. [PubMed][CrossRef]
55. Walther Z, Topazian MD. 2009. Isospora cholangiopathy: case study with histologic characterization and molecular confirmation. Hum Pathol 40:1342–1346. [PubMed][CrossRef]
56. Michiels JF, Hofman P, Bernard E, Saint Paul MC, Boissy C, Mondain V, LeFichoux Y, Loubiere R. 1994. Intestinal and extraintestinal Isospora belli infection in an AIDS patient. A second case report. Pathol Res Pract 190:1089–1093, discussion 1094. [CrossRef]
57. Abubakar I, Aliyu SH, Arumugam C, Usman NK, Hunter PR. 2007. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br J Clin Pharmacol 63:387–393. [PubMed][CrossRef]
58. Palmieri F, Cicalini S, Froio N, Rizzi EB, Goletti D, Festa A, Macrí G, Petrosillo N. 2005. Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin. Int J STD AIDS 16:515–517. [PubMed][CrossRef]
59. Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. 2000. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 132:885–888. [PubMed][CrossRef]
60. Ortega YR, Sanchez R. 2010. Update on Cyclospora cayetanensis, a food-borne and waterborne parasite. Clin Microbiol Rev 23:218–234. [PubMed][CrossRef]
61. Didier ES. 2005. Microsporidiosis: an emerging and opportunistic infection in humans and animals. Acta Trop 94:61–76. [PubMed][CrossRef]
62. Lee SC, Corradi N, Byrnes EJ III, Torres-Martinez S, Dietrich FS, Keeling PJ, Heitman J. 2008. Microsporidia evolved from ancestral sexual fungi. Curr Biol 18:1675–1679. [PubMed][CrossRef]
63. Ramanan P, Pritt BS. 2014. Extraintestinal microsporidiosis. J Clin Microbiol 52:3839–3844. [PubMed][CrossRef]
64. Didier ES, Weiss LM. 2011. Microsporidiosis: not just in AIDS patients. Curr Opin Infect Dis 24:490–495. [PubMed][CrossRef]
65. Center for Disease Control and Prevention. 2013. Microsporidiosis. Centers for Disease Control and Prevention.
66. Orenstein JM, Chiang J, Steinberg W, Smith PD, Rotterdam H, Kotler DP. 1990. Intestinal microsporidiosis as a cause of diarrhea in human immunodeficiency virus-infected patients: a report of 20 cases. Hum Pathol 21:475–481. [PubMed][CrossRef]
67. Sak B, Kváč M, Kučerová Z, Květoňová D, Saková K. 2011. Latent microsporidial infection in immunocompetent individuals - a longitudinal study. PLoS Negl Trop Dis 5:e1162. [PubMed][CrossRef]
68. Nkinin SW, Asonganyi T, Didier ES, Kaneshiro ES. 2007. Microsporidian infection is prevalent in healthy people in Cameroon. J Clin Microbiol 45:2841–2846. [PubMed][CrossRef]
69. Abreu-Acosta N, Lorenzo-Morales J, Leal-Guio Y, Coronado-Alvarez N, Foronda P, Alcoba-Florez J, Izquierdo F, Batista-Díaz N, Del Aguila C, Valladares B. 2005. Enterocytozoon bieneusi (microsporidia) in clinical samples from immunocompetent individuals in Tenerife, Canary Islands, Spain. Trans R Soc Trop Med Hyg 99:848–855. [PubMed][CrossRef]
70. Lobo ML, Xiao L, Antunes F, Matos O. 2012. Microsporidia as emerging pathogens and the implication for public health: a 10-year study on HIV-positive and -negative patients. Int J Parasitol 42:197–205. [PubMed][CrossRef]
71. Sobottka I, Schwartz DA, Schottelius J, Visvesvara GS, Pieniazek NJ, Schmetz C, Kock NP, Laufs R, Albrecht H. 1998. Prevalence and clinical significance of intestinal microsporidiosis in human immunodeficiency virus-infected patients with and without diarrhea in Germany: a prospective coprodiagnostic study. Clin Infect Dis 26:475–480. [PubMed][CrossRef]
72. Ryan NJ, Sutherland G, Coughlan K, Globan M, Doultree J, Marshall J, Baird RW, Pedersen J, Dwyer B. 1993. A new trichrome-blue stain for detection of microsporidial species in urine, stool, and nasopharyngeal specimens. J Clin Microbiol 31:3264–3269. [PubMed]
73. Moura H, Schwartz DA, Bornay-Llinares F, Sodré FC, Wallace S, Visvesvara GS. 1997. A new and improved “quick-hot Gram-chromotrope” technique that differentially stains microsporidian spores in clinical samples, including paraffin-embedded tissue sections. Arch Pathol Lab Med 121:888–893. [PubMed]
74. Verweij JJ, Stensvold CR. 2014. Molecular testing for clinical diagnosis and epidemiological investigations of intestinal parasitic infections. Clin Microbiol Rev 27:371–418. [PubMed][CrossRef]
75. Visvesvara GS. 2002. In vitro cultivation of microsporidia of clinical importance. Clin Microbiol Rev 15:401–413. [PubMed][CrossRef]
76. Rodríguez-Zaragoza S. 1994. Ecology of free-living amoebae. Crit Rev Microbiol 20:225–241. [PubMed][CrossRef]
77. Visvesvara GS, Moura H, Schuster FL. 2007. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 50:1–26. [PubMed][CrossRef]
78. Greub G, Raoult D. 2004. Microorganisms resistant to free-living amoebae. Clin Microbiol Rev 17:413–433. [PubMed][CrossRef]
79. Greub G, Raoult D. 2003. Biocides currently used for bronchoscope decontamination are poorly effective against free-living amoebae. Infect Control Hosp Epidemiol 24:784–786. [PubMed][CrossRef]
80. Rohr U, Weber S, Michel R, Selenka F, Wilhelm M. 1998. Comparison of free-living amoebae in hot water systems of hospitals with isolates from moist sanitary areas by identifying genera and determining temperature tolerance. Appl Environ Microbiol 64:1822–1824. [PubMed]
81. Marciano-Cabral F, Cabral G. 2003. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 16:273–307. [PubMed][CrossRef]
82. Nuprasert W, Putaporntip C, Pariyakanok L, Jongwutiwes S. 2010. Identification of a novel t17 genotype of acanthamoeba from environmental isolates and t10 genotype causing keratitis in Thailand. J Clin Microbiol 48:4636–4640. [PubMed][CrossRef]
83. Visvesvara GS, Martinez AJ, Schuster FL, Leitch GJ, Wallace SV, Sawyer TK, Anderson M. 1990. Leptomyxid ameba, a new agent of amebic meningoencephalitis in humans and animals. J Clin Microbiol 28:2750–2756. [PubMed]
84. Centers for Disease Control and Prevention (CDC). 2010. Notes from the field: transplant-transmitted Balamuthia mandrillaris—Arizona, 2010. MMWR Morb Mortal Wkly Rep 59:1182. [PubMed]
85. Chappell CL, Wright JA, Coletta M, Newsome AL. 2001. Standardized method of measuring acanthamoeba antibodies in sera from healthy human subjects. Clin Diagn Lab Immunol 8:724–730. [CrossRef]
86. Matin A, Siddiqui R, Jayasekera S, Khan NA. 2008. Increasing importance of Balamuthia mandrillaris. Clin Microbiol Rev 21:435–448. [PubMed][CrossRef]
87. Niyyati M, Lorenzo-Morales J, Rezaeian M, Martin-Navarro CM, Haghi AM, Maciver SK, Valladares B. 2009. Isolation of Balamuthia mandrillaris from urban dust, free of known infectious involvement. Parasitol Res 106:279–281. [PubMed][CrossRef]
88. Bravo FG, Alvarez PJ, Gotuzzo E. 2011. Balamuthia mandrillaris infection of the skin and central nervous system: an emerging disease of concern to many specialties in medicine. Curr Opin Infect Dis 24:112–117. [PubMed][CrossRef]
89. Centers for Disease Control and Prevention (CDC). 2008. Balamuthia amebic encephalitis--California, 1999-2007. MMWR Morb Mortal Wkly Rep 57:768–771. [PubMed]
90. Steinberg JP, Galindo RL, Kraus ES, Ghanem KG. 2002. Disseminated acanthamebiasis in a renal transplant recipient with osteomyelitis and cutaneous lesions: case report and literature review. Clin Infect Dis 35:e43–e49. [PubMed][CrossRef]
91. Koide J, Okusawa E, Ito T, Mori S, Takeuchi T, Itoyama S, Abe T. 1998. Granulomatous amoebic encephalitis caused by Acanthamoeba in a patient with systemic lupus erythematosus. Clin Rheumatol 17:329–332. [PubMed][CrossRef]
92. Murakawa GJ, McCalmont T, Altman J, Telang GH, Hoffman MD, Kantor GR, Berger TG. 1995. Disseminated acanthamebiasis in patients with AIDS. A report of five cases and a review of the literature. Arch Dermatol 131:1291–1296. [PubMed][CrossRef]
93. Trabelsi H, Dendana F, Sellami A, Sellami H, Cheikhrouhou F, Neji S, Makni F, Ayadi A. 2012. Pathogenic free-living amoebae: epidemiology and clinical review. Pathol Biol (Paris) 60:399–405. [PubMed][CrossRef]
94. Lorenzo-Morales J, Cabello-Vílchez AM, Martín-Navarro CM, Martínez-Carretero E, Piñero JE, Valladares B. 2013. Is Balamuthia mandrillaris a public health concern worldwide? Trends Parasitol 29:483–488. [PubMed][CrossRef]
95. Mazur T, Hadaś E, Iwanicka I. 1995. The duration of the cyst stage and the viability and virulence of Acanthamoeba isolates. Trop Med Parasitol 46:106–108. [PubMed]
96. Siddiqui R, Khan NA. 2015. Balamuthia mandrillaris: morphology, biology, and virulence. Trop Parasitol 5:15–22. [PubMed][CrossRef]
97. Barratt JL, Harkness J, Marriott D, Ellis JT, Stark D. 2010. Importance of nonenteric protozoan infections in immunocompromised people. Clin Microbiol Rev 23:795–836. [PubMed][CrossRef]
98. Schuster FL, Visvesvara GS. 2004. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 34:1001–1027. [PubMed][CrossRef]
99. Jayasekera S, Sissons J, Tucker J, Rogers C, Nolder D, Warhurst D, Alsam S, White JM, Higgins EM, Khan NA. 2004. Post-mortem culture of Balamuthia mandrillaris from the brain and cerebrospinal fluid of a case of granulomatous amoebic meningoencephalitis, using human brain microvascular endothelial cells. J Med Microbiol 53:1007–1012. [PubMed][CrossRef]
100. Centers for Disease Control and Prevention (CDC). 2008. Balamuthia amebic encephalitis--California, 1999-2007. MMWR Morb Mortal Wkly Rep 57:768–771. [PubMed]
101. Butler TK, Males JJ, Robinson LP, Wechsler AW, Sutton GL, Cheng J, Taylor P, McClellan K. 2005. Six-year review of Acanthamoeba keratitis in New South Wales, Australia: 1997-2002. Clin Experiment Ophthalmol 33:41–46. [PubMed][CrossRef]
102. Tay-Kearney ML, McGhee CN, Crawford GJ, Trown K. 1993. Acanthamoeba keratitis. A masquerade of presentation in six cases. Aust N Z J Ophthalmol 21:237–245. [PubMed][CrossRef]
103. Collier SA, Gronostaj MP, MacGurn AK, Cope JR, Awsumb KL, Yoder JS, Beach MJ, Centers for Disease Control and Prevention (CDC). 2014. Estimated burden of keratitis—United States, 2010. MMWR Morb Mortal Wkly Rep 63:1027–1030. [PubMed]
104. Heffler KF, Eckhardt TJ, Reboli AC, Stieritz D. 1996. Acanthamoeba endophthalmitis in acquired immunodeficiency syndrome. Am J Ophthalmol 122:584–586. [PubMed][CrossRef]
105. Gonzalez MM, Gould E, Dickinson G, Martinez AJ, Visvesvara G, Cleary TJ, Hensley GT. 1986. Acquired immunodeficiency syndrome associated with Acanthamoeba infection and other opportunistic organisms. Arch Pathol Lab Med 110:749–751. [PubMed]
106. Torno MS Jr, Babapour R, Gurevitch A, Witt MD. 2000. Cutaneous acanthamoebiasis in AIDS. J Am Acad Dermatol 42:351–354. [PubMed][CrossRef]
107. Qvarnstrom Y, Visvesvara GS, Sriram R, da Silva AJ. 2006. Multiplex real-time PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri. J Clin Microbiol 44:3589–3595. [PubMed][CrossRef]
108. Schroeder JM, Booton GC, Hay J, Niszl IA, Seal DV, Markus MB, Fuerst PA, Byers TJ. 2001. Use of subgenic 18S ribosomal DNA PCR and sequencing for genus and genotype identification of acanthamoebae from humans with keratitis and from sewage sludge. J Clin Microbiol 39:1903–1911. [PubMed][CrossRef]
109. Lorenzo-Morales J, Khan NA, Walochnik J. 2015. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite 22:10. [PubMed][CrossRef]
110. Newman W, Hay J, Browne B, Seal DV. 1997. Acanthamoeba as a ‘transient’ in the corneal scrape of a poorly compliant soft contact lens wearer with peripheral keratitis. Eye (Lond) 11:937–939. [PubMed][CrossRef]
111. Bacon AS, Frazer DG, Dart JK, Matheson M, Ficker LA, Wright P. 1993. A review of 72 consecutive cases of Acanthamoeba keratitis, 1984-1992. Eye (Lond) 7:719–725. [PubMed][CrossRef]
112. Seal D, Hay J, Kirkness C, Morrell A, Booth A, Tullo A, Ridgway A, Armstrong M. 1996. Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine. Eye (Lond) 10:413–421. [PubMed][CrossRef]
113. McBride J, Ingram PR, Henriquez FL, Roberts CW. 2005. Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba. J Clin Microbiol 43:629–634. [PubMed][CrossRef]
114. Martínez DY, Seas C, Bravo F, Legua P, Ramos C, Cabello AM, Gotuzzo E. 2010. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. Clin Infect Dis 51:e7–e11. [PubMed][CrossRef]
115. Deetz TR, Sawyer MH, Billman G, Schuster FL, Visvesvara GS. 2003. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. Clin Infect Dis 37:1304–1312. [PubMed][CrossRef]
116. Robert-Gangneux F, Dardé ML. 2012. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 25:264–296. [PubMed][CrossRef]
117. Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet 363:1965–1976. [PubMed][CrossRef]
118. Liesenfeld O. 1999. Immune responses to Toxoplasma gondii in the gut. Immunobiology 201:229–239. [PubMed][CrossRef]
119. Montoya JG, Remington JS. 1996. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis 23:277–282. [PubMed][CrossRef]
120. Luft BJ, Remington JS. 1992. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 15:211–222. [PubMed][CrossRef]
121. Guk SM, Seo M, Park YK, Oh MD, Choe KW, Kim JL, Choi MH, Hong ST, Chai JY. 2005. Parasitic infections in HIV-infected patients who visited Seoul National University Hospital during the period 1995-2003. Korean J Parasitol 43:1–5. [PubMed][CrossRef]
122. Piccolo I, Causarano R, Sterzi R, Sberna M, Oreste PL, Moioli C, Caggese L, Girotti F. 1999. Chorea in patients with AIDS. Acta Neurol Scand 100:332–336. [PubMed][CrossRef]
123. Merzianu M, Gorelick SM, Paje V, Kotler DP, Sian C. 2005. Gastric toxoplasmosis as the presentation of acquired immunodeficiency syndrome. Arch Pathol Lab Med 129:e87–e90. [PubMed]
124. Koeppel MC, Abitan R, Angeli C, Lafon J, Pelletier J, Sayag J. 1998. Cutaneous and gastrointestinal mastocytosis associated with cerebral toxoplasmosis. Br J Dermatol 139:881–884. [PubMed][CrossRef]
125. Zver S, Cernelc P, Mlakar U, Pretnar J. 1999. Cerebral toxoplasmosis - a late complication of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 24:1363–1365. [PubMed][CrossRef]
126. Maschke M, Dietrich U, Prumbaum M, Kastrup O, Turowski B, Schaefer UW, Diener HC. 1999. Opportunistic CNS infection after bone marrow transplantation. Bone Marrow Transplant 23:1167–1176. [PubMed][CrossRef]
127. Khoury H, Adkins D, Brown R, Goodnough L, Gokden M, Roberts T, Storch G, DiPersio J. 1999. Successful treatment of cerebral toxoplasmosis in a marrow transplant recipient: contribution of a PCR test in diagnosis and early detection. Bone Marrow Transplant 23:409–411. [PubMed][CrossRef]
128. Dietrich U, Maschke M, Dörfler A, Prumbaum M, Forsting M. 2000. MRI of intracranial toxoplasmosis after bone marrow transplantation. Neuroradiology 42:14–18. [PubMed][CrossRef]
129. Menotti J, Vilela G, Romand S, Garin YJ, Ades L, Gluckman E, Derouin F, Ribaud P. 2003. Comparison of PCR-enzyme-linked immunosorbent assay and real-time PCR assay for diagnosis of an unusual case of cerebral toxoplasmosis in a stem cell transplant recipient. J Clin Microbiol 41:5313–5316. [PubMed][CrossRef]
130. Minkoff H, Remington JS, Holman S, Ramirez R, Goodwin S, Landesman S. 1997. Vertical transmission of toxoplasma by human immunodeficiency virus-infected women. Am J Obstet Gynecol 176:555–559. [PubMed][CrossRef]
131. Montoya JG. 2002. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis 185(Suppl 1):S73–S82. [PubMed][CrossRef]
132. Wulf MW, van Crevel R, Portier R, Ter Meulen CG, Melchers WJ, van der Ven A, Galama JM. 2005. Toxoplasmosis after renal transplantation: implications of a missed diagnosis. J Clin Microbiol 43:3544–3547. [PubMed][CrossRef]
133. Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M. 2004. Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect 132:541–548. [PubMed][CrossRef]
134. Luft BJ, Billingham M, Remington JS. 1986. Endomyocardial biopsy in the diagnosis of toxoplasmic myocarditis. Transplant Proc 18:1871–1873. [PubMed]
135. Abramowicz M. 2004. Drugs for parasitic infections. Med Lett 46:1–12.
136. Ribera E, Fernandez-Sola A, Juste C, Rovira A, Romero FJ, Armadans-Gil L, Ruiz I, Ocaña I, Pahissa A. 1999. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 29:1461–1466. [PubMed][CrossRef]
137. Colebunders R, Depraetere K, De Droogh E, Kamper A, Corthout B, Bottiau E. 1999. Obstructive nephropathy due to sulfa crystals in two HIV seropositive patients treated with sulfadiazine. JBR-BTR 82:153–154. [PubMed]
138. Arendt G, von Giesen HJ, Hefter H, Neuen-Jacob E, Roick H, Jablonowski H. 1999. Long-term course and outcome in AIDS patients with cerebral toxoplasmosis. Acta Neurol Scand 100:178–184. [PubMed][CrossRef]
139. Kaplan JE, Masur H, Holmes KK, USPHS, Infectious Disease Society of America. 2002. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51(RR-8):1–52.
140. Hill SL, Cheney JM, Taton-Allen GF, Reif JS, Bruns C, Lappin MR. 2000. Prevalence of enteric zoonotic organisms in cats. J Am Vet Med Assoc 216:687–692. [PubMed][CrossRef]
141. Organization WH. 1990. Control of the leishmaniases. World Health Organ Tech Rep Ser 793:1–158. back cover.
142. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team. 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7:e35671. [PubMed][CrossRef]
143. Marlier S, Menard G, Gisserot O, Kologo K, De Jaureguiberry JP. 1999. Leishmaniasis and human immunodeficiency virus: an emerging co-infection?. Med Trop (Mars) 59:193–200.
144. Moreno-Camacho A, López-Vélez R, Muñoz Sanz A, Labarga-Echevarría P. 1998. Intestinal parasitic infections and leishmaniasis in patients with HIV infection. Enferm Infecc Microbiol Clin 16(Suppl 1):52–60. [PubMed]
145. van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. 2014. Leishmaniasis in immunosuppressed individuals. Clinical Microbiol Infect 20:286–299. [PubMed][CrossRef]
146. Calza L, D’Antuono A, Marinacci G, Manfredi R, Colangeli V, Passarini B, Orioli R, Varoli O, Chiodo F. 2004. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS. J Am Acad Dermatol 50:461–465. [PubMed][CrossRef]
147. Saporito L, Giammanco GM, De Grazia S, Colomba C. 2013. Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host. Int J Infect Dis 17:e572–576. [PubMed][CrossRef]
148. Kamhawi S. 2006. Phlebotomine sand flies and Leishmania parasites: friends or foes? Trends Parasitol 22:439–445. [PubMed][CrossRef]
149. Tektonidou MG, Skopouli FN. 2008. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol 27:541–542. [PubMed][CrossRef]
150. Kaye P, Scott P. 2011. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9:604–615. [PubMed][CrossRef]
151. Cota GF, de Sousa MR, Rabello A. 2011. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 5:e1153. [PubMed][CrossRef]
152. Moreno J, Cañavate C, Chamizo C, Laguna F, Alvar J. 2000. HIV—Leishmania infantum co-infection: humoral and cellular immune responses to the parasite after chemotherapy. Trans R Soc Trop Med Hyg 94:328–332. [PubMed][CrossRef]
153. Bogdan C, Röllinghoff M. 1998. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 28:121–134. [PubMed][CrossRef]
154. Riera C, Fisa R, Udina M, Gállego M, Portus M. 2004. Detection of Leishmania infantum cryptic infection in asymptomatic blood donors living in an endemic area (Eivissa, Balearic Islands, Spain) by different diagnostic methods. Trans R Soc Trop Med Hyg 98:102–110. [CrossRef]
155. Colomba C, Saporito L, Vitale F, Reale S, Vitale G, Casuccio A, Tolomeo M, Maranto D, Rubino R, Di Carlo P, Titone L. 2009. Cryptic Leishmania infantum infection in Italian HIV infected patients. BMC Infect Dis 9:199. [PubMed][CrossRef]
156. Da-Cruz AM, Filgueiras DV, Coutinho Z, Mayrink W, Grimaldi G Jr, De Luca PM, Mendonca SC, Coutinho SG. 1999. Atypical mucocutaneous leishmaniasis caused by Leishmania braziliensis in an acquired immunodeficiency syndrome patient: T-cell responses and remission of lesions associated with antigen immunotherapy. Mem Inst Oswaldo Cruz 94:537–542. [PubMed][CrossRef]
157. Couppié P, Clyti E, Sobesky M, Bissuel F, Del Giudice P, Sainte-Marie D, Dedet JP, Carme B, Pradinaud R. 2004. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 151:1165–1171. [PubMed][CrossRef]
158. Dedet JP, Pratlong F. 2000. Leishmania, Trypanosoma and monoxenous trypanosomatids as emerging opportunistic agents. J Eukaryot Microbiol 47:37–39. [PubMed][CrossRef]
159. Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto H. 2005. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 192:1819–1822. [PubMed][CrossRef]
160. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. 2008. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 8:191–199. [PubMed][CrossRef]
161. Bouchekoua M, Trabelsi S, Ben Abdallah T, Khaled S. 2014. Visceral leishmaniasis after kidney transplantation: report of a new case and a review of the literature. Transplant Rev (Orlando) 28:32–35. [PubMed][CrossRef]
162. Saran R, Sharma MC, Gupta AK, Sinha SP, Kar SK. 1997. Diurnal periodicity of Leishmania amastigotes in peripheral blood of Indian Kala-azar patients. Acta Trop 68:357–360. [PubMed][CrossRef]
163. Molina I, Fisa R, Riera C, Falcó V, Elizalde A, Salvador F, Crespo M, Curran A, López-Chejade P, Tebar S, Pérez-Hoyos S, Ribera E, Pahissa A. 2013. Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients. Am J Trop Med Hyg 89:105–110. [PubMed][CrossRef]
164. Maia Z, Lírio M, Mistro S, Mendes CM, Mehta SR, Badaro R. 2012. Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis. PLoS Negl Trop Dis 6:e1484. [PubMed][CrossRef]
165. Badaró R, Reed SG, Barral A, Orge G, Jones TC. 1986. Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg 35:72–78. [PubMed]
166. Kilic S, Ozkan A, Babur C, Tanir G, Schallig H. 2008. Evaluation of serological tests for the diagnosis of visceral leishmaniasis. Turk J Med Sci 38:12–19.
167. Burns JM Jr, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG. 1993. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci USA 90:775–779. [PubMed][CrossRef]
168. Molinet FJ, Ampuero JS, Costa RD, Noronha EF, Romero GA. 2013. Specificity of the rapid rK39 antigen-based immunochromatographic test Kalazar Detect(r) in patients with cutaneous leishmaniasis in Brazil. Mem Inst Oswaldo Cruz 108:108. [PubMed][CrossRef]
169. Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW. 2006. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol 44:251–253. [PubMed][CrossRef]
170. Schwartz BS, Mawhorter SD, AST Infectious Diseases Community of Practice. 2013. Parasitic infections in solid organ transplantation. Am J Transplant 13(Suppl 4):280–303. [PubMed][CrossRef]
171. Prevention CfDCa. 2013. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
172. Meyerhoff A. 1999. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28:42–48, discussion 49–51. [PubMed][CrossRef]
173. López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejías ME, Górgolas M, Arribas JR, Salas A, Laguna F, Sust M, Cañavate C, Alvar J, Spanish HIV-Leishmania Study Group. 2004. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 53:540–543. [PubMed][CrossRef]
174. Clemente WT, Rabello A, Faria LC, Peruhype-Magalhães V, Gomes LI, da Silva TA, Nunes RV, Iodith JB, Protil KZ, Fernandes HR, Cortes JR, Lima SS, Lima AS, Romanelli RM. 2014. High prevalence of asymptomatic Leishmania spp. infection among liver transplant recipients and donors from an endemic area of Brazil. Am J Transplant 14:96–101. [PubMed][CrossRef]
175. Bern C, Kjos S, Yabsley MJ, Montgomery SP. 2011. Trypanosoma cruzi and Chagas’ Disease in the United States. Clin Microbiol Rev 24:655–681. [PubMed][CrossRef]
176. de Moraes MH, Guarneri AA, Girardi FP, Rodrigues JB, Eger I, Tyler KM, Steindel M, Grisard EC. 2008. Different serological cross-reactivity of Trypanosoma rangeli forms in Trypanosoma cruzi-infected patients sera. Parasit Vectors 1:20. [PubMed][CrossRef]
177. Coster LO. 2013. Parasitic infections in solid organ transplant recipients. Infect Dis Clin North Am 27:395–427. [PubMed][CrossRef]
178. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. 2008. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2:e300. [PubMed][CrossRef]
179. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S. 2003. The trypanosomiases. Lancet 362:1469–1480. [PubMed][CrossRef]
180. Hotez PJ, Dumonteil E, Woc-Colburn L, Serpa JA, Bezek S, Edwards MS, Hallmark CJ, Musselwhite LW, Flink BJ, Bottazzi ME. 2012. Chagas disease: “the new HIV/AIDS of the Americas.” PLoS Negl Trop Dis 6:e1498. [PubMed][CrossRef]
181. Riarte A, Luna C, Sabatiello R, Sinagra A, Schiavelli R, De Rissio A, Maiolo E, Garcìa MM, Jacob N, Pattin M, Lauricella M, Segura EL, Vázquez M. 1999. Chagas’ disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis 29:561–567. [PubMed][CrossRef]
182. Kayama H, Takeda K. 2010. The innate immune response to Trypanosoma cruzi infection. Microbes Infect 12:511–517. [PubMed][CrossRef]
183. Teixeira AR, Hecht MM, Guimaro MC, Sousa AO, Nitz N. 2011. Pathogenesis of chagas’ disease: parasite persistence and autoimmunity. Clin Microbiol Rev 24:592–630. [PubMed][CrossRef]
184. Rassi A Jr, Rassi A, Marin-Neto JA. 2010. Chagas disease. Lancet 375:1388–1402. [PubMed][CrossRef]
185. Alarcón de Noya B, Díaz-Bello Z, Colmenares C, Ruiz-Guevara R, Mauriello L, Zavala-Jaspe R, Suarez JA, Abate T, Naranjo L, Paiva M, Rivas L, Castro J, Márques J, Mendoza I, Acquatella H, Torres J, Noya O. 2010. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis 201:1308–1315. [PubMed][CrossRef]
186. de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. 1998. Gastrointestinal manifestations of Chagas’ disease. Am J Gastroenterol 93:884–889. [PubMed][CrossRef]
187. Centers for Disease Control and Prevention. 2006. Chagas disease after organ transplantation—Los Angeles, California. Morb Mortal Wkly Rep 55:798–800. [PubMed]
188. Altclas JD, Barcan L, Nagel C, Lattes R, Riarte A. 2008. Organ transplantation and Chagas disease. JAMA 299:1134, author reply 1134–1135. [PubMed][CrossRef]
189. Lattes R, Lasala MB. 2014. Chagas disease in the immunosuppressed patient. Clin Microbiol Infect 20:300–309. [PubMed][CrossRef]
190. Godoy HL, Guerra CM, Viegas RF, Dinis RZ, Branco JN, Neto VA, Almeida DR. 2010. Infections in heart transplant recipients in Brazil: the challenge of Chagas’ disease. J Heart Lung Transplant 29:286–290. [PubMed][CrossRef]
191. Qvarnstrom Y, Schijman AG, Veron V, Aznar C, Steurer F, da Silva AJ. 2012. Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multi-target real-time PCR approach. PLoS Negl Trop Dis 6:e1689.
192. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. 2007. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298:2171–2181. [PubMed][CrossRef]
193. Malan AK, Avelar E, Litwin SE, Hill HR, Litwin CM. 2006. Serological diagnosis of Trypanosoma cruzi: evaluation of three enzyme immunoassays and an indirect immunofluorescent assay. J Med Microbiol 55:171–178. [PubMed][CrossRef]
194. Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, Morris MI, Nowicki M, Wright C, Ison MG. 2011. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant 11:672–680. [PubMed][CrossRef]
195. Cazorla SI, Frank FM, Malchiodi EL. 2009. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 8:921–935. [PubMed][CrossRef]
196. Cox FE. 2010. History of the discovery of the malaria parasites and their vectors. Parasit Vectors 3:5. [PubMed][CrossRef]
197. White NJ, Turner GD, Day NP, Dondorp AM. 2013. Lethal malaria: Marchiafava and Bignami were right. J Infect Dis 208:192–198. [PubMed][CrossRef]
198. World Health Organization. 2014. World Malaria Report 2014. World Health Organization, Geneva, Switzerland.
199. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, Snow RW. 2008. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 5:e38. [PubMed][CrossRef]
200. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214–217. [PubMed][CrossRef]
201. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. 2014. Malaria. Lancet 383:723–735. [PubMed][CrossRef]
202. White NJ. 2008. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis 46:172–173. [PubMed][CrossRef]
203. Lee KS, Cox-Singh J, Brooke G, Matusop A, Singh B. 2009. Plasmodium knowlesi from archival blood films: further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo. Int J Parasitol 39:1125–1128. [PubMed][CrossRef]
204. Dondorp AM, Lee SJ, Faiz MA, Mishra S, Price R, Tjitra E, Than M, Htut Y, Mohanty S, Yunus EB, Rahman R, Nosten F, Anstey NM, Day NP, White NJ. 2008. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 47:151–157. [PubMed][CrossRef]
205. Cullen KA, Arguin PM, Centers for Disease Control and Prevention (CDC). 2014. Malaria surveillance—United States, 2012. MMWR Surveill Summ 63:1–22. [PubMed]
206. Harbach RE. 2004. The classification of genus Anopheles (Diptera: Culicidae): a working hypothesis of phylogenetic relationships. Bull Entomol Res 94:537–553. [PubMed][CrossRef]
207. Filler S, Causer LM, Newman RD, Barber AM, Roberts JM, MacArthur J, Parise ME, Steketee RW, Centers for Disease Control and Prevention (CDC). 2003. Malaria surveillance—United States, 2001. MMWR Surveill Summ 52:1–14. [PubMed]
208. Newbold C, Craig A, Kyes S, Rowe A, Fernandez-Reyes D, Fagan T. 1999. Cytoadherence, pathogenesis and the infected red cell surface in Plasmodium falciparum. Int J Parasitol 29:927–937. [PubMed][CrossRef]
209. McGuire W, Knight JC, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. 1999. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis 179:287–290. [PubMed][CrossRef]
210. Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki S, Nahlen BL, Lal AA, Udhayakumar V. 2002. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 359:1311–1312. [PubMed][CrossRef]
211. Enevold A, Lusingu JP, Mmbando B, Alifrangis M, Lemnge MM, Bygbjerg IC, Theander TG, Vestergaard LS. 2008. Reduced risk of uncomplicated malaria episodes in children with alpha+-thalassemia in northeastern Tanzania. Am J Trop Med Hyg 78:714–720. [PubMed]
212. Mibei EK, Otieno WO, Orago AS, Stoute JA. 2008. Distinct pattern of class and subclass antibodies in immune complexes of children with cerebral malaria and severe malarial anaemia. Parasite Immunol 30:334–341. [PubMed][CrossRef]
213. Van Geertruyden JP. 2014. Interactions between malaria and human immunodeficiency virus anno 2014. Clin Microbiol Infect 20:278–285. [PubMed][CrossRef]
214. Wilson ME, Weld LH, Boggild A, Keystone JS, Kain KC, von Sonnenburg F, Schwartz E, GeoSentinel Surveillance Network. 2007. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 44:1560–1568. [PubMed][CrossRef]
215. Svenson JE, MacLean JD, Gyorkos TW, Keystone J. 1995. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 155:861–868. [PubMed][CrossRef]
216. Baird JK. 2014. Pernicious and threatening Plasmodium vivax as reality. Am J Trop Med Hyg 91:1–2. [PubMed][CrossRef]
217. Joshi H, Prajapati SK, Verma A, Kang’a S, Carlton JM. 2008. Plasmodium vivax in India. Trends Parasitol 24:228–235. [PubMed][CrossRef]
218. Ehrich JH, Eke FU. 2007. Malaria-induced renal damage: facts and myths. Pediatr Nephrol 22:626–637. [PubMed][CrossRef]
219. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, Rahman HA, Conway DJ, Singh B. 2008. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 46:165–171. [PubMed][CrossRef]
220. Organization WH. 2014. Severe malaria. Trop Med Int Health 19(Suppl 1):7–131. [PubMed][CrossRef]
221. White NJ. 1996. The treatment of malaria. N Engl J Med 335:800–806. [PubMed][CrossRef]
222. Patnaik P, Jere CS, Miller WC, Hoffman IF, Wirima J, Pendame R, Meshnick SR, Taylor TE, Molyneux ME, Kublin JG. 2005. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis 192:984–991. [PubMed][CrossRef]
223. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, Rosenthal PJ, Dorsey G, Havlir D. 2006. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 193:9–15. [PubMed][CrossRef]
224. Van Geertruyden JP, Mulenga M, Mwananyanda L, Chalwe V, Moerman F, Chilengi R, Kasongo W, Van Overmeir C, Dujardin JC, Colebunders R, Kestens L, D’Alessandro U. 2006. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 194:917–925. [PubMed][CrossRef]
225. Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S, FHDH-ANRS CO4 Clinical Epidemiology Group. 2009. Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts <350 cells/microl. AIDS 23:1997–2004. [PubMed][CrossRef]
226. Chiche L, Lesage A, Duhamel C, Salame E, Malet M, Samba D, Segol P, Treilhaud M. 2003. Posttransplant malaria: first case of transmission of Plasmodium falciparum from a white multiorgan donor to four recipients. Transplantation 75:166–168. [PubMed][CrossRef]
227. McKenzie FE, Prudhomme WA, Magill AJ, Forney JR, Permpanich B, Lucas C, Gasser RA Jr, Wongsrichanalai C. 2005. White blood cell counts and malaria. J Infect Dis 192:323–330. [PubMed][CrossRef]
228. Griffith KS, Lewis LS, Mali S, Parise ME. 2007. Treatment of malaria in the United States: a systematic review. JAMA 297:2264–2277. [PubMed][CrossRef]
229. Erdman LK, Kain KC. 2008. Molecular diagnostic and surveillance tools for global malaria control. Travel Med Infect Dis 6:82–99. [PubMed][CrossRef]
230. Padial MM, Subirats M, Puente S, Lago M, Crespo S, Palacios G, Baquero M. 2005. Sensitivity of laser light depolarization analysis for detection of malaria in blood samples. J Med Microbiol 54:449–452. [PubMed][CrossRef]
231. Tangpukdee N, Duangdee C, Wilairatana P, Krudsood S. 2009. Malaria diagnosis: a brief review. Korean J Parasitol 47:93–102. [PubMed][CrossRef]
232. Mixson-Hayden T, Lucchi NW, Udhayakumar V. 2010. Evaluation of three PCR-based diagnostic assays for detecting mixed Plasmodium infection. BMC Res Notes 3:88. [PubMed][CrossRef]
233. Babiker HA, Schneider P, Reece SE. 2008. Gametocytes: insights gained during a decade of molecular monitoring. Trends Parasitol 24:525–530. [PubMed][CrossRef]
234. World Health Organization. 2012. Malaria RDT product testing: interactive guide. World Health Organization, Geneva, Switzerland.
235. McCutchan TF, Piper RC, Makler MT. 2008. Use of malaria rapid diagnostic test to identify Plasmodium knowlesi infection. Emerg Infect Dis 14:1750–1752. [PubMed][CrossRef]
236. Marx A, Pewsner D, Egger M, Nüesch R, Bucher HC, Genton B, Hatz C, Jüni P. 2005. Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med 142:836–846. [PubMed][CrossRef]
237. Stauffer WM, Cartwright CP, Olson DA, Juni BA, Taylor CM, Bowers SH, Hanson KL, Rosenblatt JE, Boulware DR. 2009. Diagnostic performance of rapid diagnostic tests versus blood smears for malaria in US clinical practice. Clin Infect Dis 49:908–913. [PubMed][CrossRef]
238. She RC, Rawlins ML, Mohl R, Perkins SL, Hill HR, Litwin CM. 2007. Comparison of immunofluorescence antibody testing and two enzyme immunoassays in the serologic diagnosis of malaria. J Travel Med 14:105–111. [PubMed][CrossRef]
239. Centers for Disease Control and Prevention. 2013. Guidelines for Treatment of Malaria in the United States. Centers for Disease Control and Prevention, Atlanta, GA.
240. Weetman D, Donnelly MJ. 2015. Evolution of insecticide resistance diagnostics in malaria vectors. Trans R Soc Trop Med Hyg 109:291–293. [PubMed][CrossRef]
241. Ellis RD, Sagara I, Doumbo O, Wu Y. 2010. Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vaccin 6:627–634. [PubMed][CrossRef]
242. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, Shomari M, Leach A, Fernandes J, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Apanga S, Mwangoka G, Okissi B, Kwara E, Minja R, Lange J, Boahen O, Kayan K, Adjei G, Chandramohan D, Jongert E, Demoitié MA, Dubois MC, Carter T, Vansadia P, Villafana T, Sillman M, Savarese B, Lapierre D, Ballou WR, Greenwood B, Tanner M, Cohen J, Kremsner PG, Lell B, Owusu-Agyei S, Abdulla S. 2010. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 202:1076–1087. [PubMed][CrossRef]
243. Herwaldt B, Persing DH, Précigout EA, Goff WL, Mathiesen DA, Taylor PW, Eberhard ML, Gorenflot AF. 1996. A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann Intern Med 124:643–650. [PubMed][CrossRef]
244. Herwaldt BL, de Bruyn G, Pieniazek NJ, Homer M, Lofy KH, Slemenda SB, Fritsche TR, Persing DH, Limaye AP. 2004. Babesia divergens-like infection, Washington State. Emerg Infect Dis 10:622–629. [PubMed][CrossRef]
245. Beattie JF, Michelson ML, Holman PJ. 2002. Acute babesiosis caused by Babesia divergens in a resident of Kentucky. N Engl J Med 347:697–698. [PubMed][CrossRef]
246. Herwaldt BL, Cacciò S, Gherlinzoni F, Aspöck H, Slemenda SB, Piccaluga P, Martinelli G, Edelhofer R, Hollenstein U, Poletti G, Pampiglione S, Löschenberger K, Tura S, Pieniazek NJ. 2003. Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe. Emerg Infect Dis 9:942–948. [PubMed][CrossRef]
247. Quick RE, Herwaldt BL, Thomford JW, Garnett ME, Eberhard ML, Wilson M, Spach DH, Dickerson JW, Telford SR III, Steingart KR, Pollock R, Persing DH, Kobayashi JM, Juranek DD, Conrad PA. 1993. Babesiosis in Washington State: a new species of Babesia? Ann Intern Med 119:284–290. [PubMed][CrossRef]
248. Vannier E, Krause PJ. 2012. Human babesiosis. N Engl J Med 366:2397–2407. [PubMed][CrossRef]
249. Hunfeld KP, Lambert A, Kampen H, Albert S, Epe C, Brade V, Tenter AM. 2002. Seroprevalence of Babesia infections in humans exposed to ticks in midwestern Germany. J Clin Microbiol 40:2431–2436. [PubMed][CrossRef]
250. Häselbarth K, Tenter AM, Brade V, Krieger G, Hunfeld KP. 2007. First case of human babesiosis in Germany - clinical presentation and molecular characterisation of the pathogen. Int J Med Microbiol 297:197–204. [PubMed][CrossRef]
251. Gubernot DM, Lucey CT, Lee KC, Conley GB, Holness LG, Wise RP. 2009. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis 48:25–30. [PubMed][CrossRef]
252. Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR III, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. 2008. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 46:370–376. [PubMed][CrossRef]
253. Krause PJ, Daily J, Telford SR, Vannier E, Lantos P, Spielman A. 2007. Shared features in the pathobiology of babesiosis and malaria. Trends Parasitol 23:605–610. [PubMed][CrossRef]
254. Vannier E, Gewurz BE, Krause PJ. 2008. Human babesiosis. Infect Dis Clin North Am 22:469–488, viii–ix. [PubMed][CrossRef]
255. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. 2011. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 155:509–519. [PubMed][CrossRef]
256. Fox LM, Wingerter S, Ahmed A, Arnold A, Chou J, Rhein L, Levy O. 2006. Neonatal babesiosis: case report and review of the literature. Pediatr Infect Dis J 25:169–173. [PubMed][CrossRef]
257. White DJ, Talarico J, Chang HG, Birkhead GS, Heimberger T, Morse DL. 1998. Human babesiosis in New York State: review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med 158:2149–2154. [PubMed][CrossRef]
258. Zintl A, Mulcahy G, Skerrett HE, Taylor SM, Gray JS. 2003. Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance. Clin Microbiol Rev 16:622–636. [PubMed][CrossRef]
259. Krause PJ. 2003. Babesiosis diagnosis and treatment. Vector Borne Zoonotic Dis 3:45–51. [PubMed][CrossRef]
260. Persing DH, Mathiesen D, Marshall WF, Telford SR, Spielman A, Thomford JW, Conrad PA. 1992. Detection of Babesia microti by polymerase chain reaction. J Clin Microbiol 30:2097–2103. [PubMed]
261. Krause PJ, Spielman A, Telford SR III, Sikand VK, McKay K, Christianson D, Pollack RJ, Brassard P, Magera J, Ryan R, Persing DH. 1998. Persistent parasitemia after acute babesiosis. N Engl J Med 339:160–165. [PubMed][CrossRef]
262. Wilson M, Glaser KC, Adams-Fish D, Boley M, Mayda M, Molestina RE. 2015. Development of droplet digital PCR for the detection of Babesia microti and Babesia duncani. Exp Parasitol 149:24–31. [PubMed][CrossRef]
263. Krause PJ, Ryan R, Telford S III, Persing D, Spielman A. 1996. Efficacy of immunoglobulin M serodiagnostic test for rapid diagnosis of acute babesiosis. J Clin Microbiol 34:2014–2016. [PubMed]
264. Ruebush TK II, Chisholm ES, Sulzer AJ, Healy GR. 1981. Development and persistence of antibody in persons infected with Babesia microti. Am J Trop Med Hyg 30:291–292. [PubMed]
265. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. 2006. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089–1134. [PubMed][CrossRef]
266. Krause PJ, Lepore T, Sikand VK, Gadbaw J Jr, Burke G, Telford SR III, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A. 2000. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 343:1454–1458. [PubMed][CrossRef]
267. Velásquez JN, Carnevale S, Oelemann WM, Etchart C, Peralta JM. 2005. Diagnosis of Enterocytozoon bieneusi by the polymerase chain reaction in archival fixed duodenal tissue. Enferm Infecc Microbiol Clin 23:218–220. [PubMed][CrossRef]
268. Ashford RW, Barnish G, Viney ME. 1992. Strongyloides fuelleborni kellyi: infection and disease in Papua New Guinea. Parasitol Today 8:314–318. [PubMed][CrossRef]
269. Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, Chen X. 2014. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis 8:e3018. [PubMed][CrossRef]
270. Croker C, Reporter R, Redelings M, Mascola L. 2010. Strongyloidiasis-related deaths in the United States, 1991-2006. Am J Trop Med Hyg 83:422–426. [PubMed][CrossRef]
271. Posey DL, Blackburn BG, Weinberg M, Flagg EW, Ortega L, Wilson M, Secor WE, Sanders-Lewis K, Won K, Maguire JH. 2007. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis 45:1310–1315. [PubMed][CrossRef]
272. Viney ME. 1996. Developmental switching in the parasitic nematode Strongyloides ratti. Proc Biol Sci 263:201–208. [PubMed][CrossRef]
273. Chu E, Whitlock WL, Dietrich RA. 1990. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest 97:1475–1477. [PubMed][CrossRef]
274. Pelletier LL Jr, Baker CB, Gam AA, Nutman TB, Neva FA. 1988. Diagnosis and evaluation of treatment of chronic strongyloidiasis in ex-prisoners of war. J Infect Dis 157:573–576. [PubMed][CrossRef]
275. Iriemenam NC, Sanyaolu AO, Oyibo WA, Fagbenro-Beyioku AF. 2010. Strongyloides stercoralis and the immune response. Parasitol Int 59:9–14. [PubMed][CrossRef]
276. Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, Bisoffi Z. 2013. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 13:78. [PubMed][CrossRef]
277. Ghosh K, Ghosh K. 2007. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg 101:1163–1165. [PubMed][CrossRef]
278. Gotuzzo E, Arango C, de Queiroz-Campos A, Istúriz RE. 2000. Human T-cell lymphotropic virus-I in Latin America. Infect Dis Clin North Am 14:211–239, x–xi. x-xi. [CrossRef]
279. Gotuzzo E, Terashima A, Alvarez H, Tello R, Infante R, Watts DM, Freedman DO. 1999. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg 60:146–149. [PubMed]
280. Hayashi J, Kishihara Y, Yoshimura E, Furusyo N, Yamaji K, Kawakami Y, Murakami H, Kashiwagi S. 1997. Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. Am J Trop Med Hyg 56:71–75. [PubMed]
281. Agapé P, Copin MC, Cavrois M, Panelatti G, Plumelle Y, Ossondo-Landeau M, Quist D, Grossat N, Gosselin B, Fenaux P, Wattel E. 1999. Implication of HTLV-I infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin’s lymphomas in an endemic area (Martinique, French West Indies). J Acquir Immune Defic Syndr Hum Retrovirol 20:394–402. [PubMed][CrossRef]
282. Robinson RD, Lindo JF, Neva FA, Gam AA, Vogel P, Terry SI, Cooper ES. 1994. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 169:692–696. [PubMed][CrossRef]
283. Siddiqui AA, Berk SL. 2001. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 33:1040–1047. [PubMed][CrossRef]
284. Abdalla J, Saad M, Myers JW, Moorman JP. 2005. An elderly man with immunosuppression, shortness of breath, and eosinophilia. Clin Infect Dis 40:1464, 1535–1536. [PubMed][CrossRef]
285. Requena-Mendez A, Chiodini P, Bisoffi Z, Buonfrate D, Gotuzzo E, Munoz J. 2013. The laboratory diagnosis and follow up of strongyloidiasis: a systematic review. PLoS Negl Trop Dis 7:e2002.
286. Rosenblatt JE. 2006. Clinical importance of adequately performed stool ova and parasite examinations. Clin Infect Dis 42:979–980. [PubMed][CrossRef]
287. Kramme S, Nissen N, Soblik H, Erttmann K, Tannich E, Fleischer B, Panning M, Brattig N. 2011. Novel real-time PCR for the universal detection of Strongyloides species. J Med Microbiol 60:454–458. [PubMed][CrossRef]
288. Verweij JJ, Canales M, Polman K, Ziem J, Brienen EA, Polderman AM, van Lieshout L. 2009. Molecular diagnosis of Strongyloides stercoralis in faecal samples using real-time PCR. Trans R Soc Trop Med Hyg 103:342–346. [PubMed][CrossRef]
289. Levenhagen MA, Costa-Cruz JM. 2014. Update on immunologic and molecular diagnosis of human strongyloidiasis. Acta Trop 135:33–43. [PubMed][CrossRef]
290. Loutfy MR, Wilson M, Keystone JS, Kain KC. 2002. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 66:749–752. [PubMed]
291. van Doorn HR, Koelewijn R, Hofwegen H, Gilis H, Wetsteyn JC, Wismans PJ, Sarfati C, Vervoort T, van Gool T. 2007. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 45:438–442. [PubMed][CrossRef]
292. Ramanathan R, Burbelo PD, Groot S, Iadarola MJ, Neva FA, Nutman TB. 2008. A luciferase immunoprecipitation systems assay enhances the sensitivity and specificity of diagnosis of Strongyloides stercoralis infection. J Infect Dis 198:444–451. [PubMed][CrossRef]
293. Anderson NW, Klein DM, Dornink SM, Jespersen DJ, Kubofcik J, Nutman TB, Merrigan SD, Couturier MR, Theel ES. 2014. Comparison of three immunoassays for detection of antibodies to Strongyloides stercoralis. Clin Vaccine Immunol 21:732–736. [PubMed][CrossRef]
294. Krolewiecki AJ, Ramanathan R, Fink V, McAuliffe I, Cajal SP, Won K, Juarez M, Di Paolo A, Tapia L, Acosta N, Lee R, Lammie P, Abraham D, Nutman TB. 2010. Improved diagnosis of Strongyloides stercoralis using recombinant antigen-based serologies in a community-wide study in northern Argentina. Clin Vaccine Immunol 17:1624–1630. [PubMed][CrossRef]
295. Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sánchez-Sánchez P, Matogo-Oyana J, Rodríguez-Calabuig D. 2004. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 5:2615–2619. [PubMed][CrossRef]
296. Muennig P, Pallin D, Challah C, Khan K. 2004. The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States. Epidemiol Infect 132:1055–1063. [PubMed][CrossRef]
297. Segarra-Newnham M. 2007. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 41:1992–2001. [PubMed][CrossRef]
298. Keiser PB, Nutman TB. 2004. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 17:208–217. [CrossRef]
299. Chosidow O. 2006. Clinical practices. Scabies. N Engl J Med 354:1718–1727. [PubMed][CrossRef]
300. Walton SF, Currie BJ. 2007. Problems in diagnosing scabies, a global disease in human and animal populations. Clin Microbiol Rev 20:268–279. [PubMed][CrossRef]
301. Heukelbach J, Feldmeier H. 2006. Scabies. Lancet 367:1767–1774. [PubMed][CrossRef]
302. Vos T, et al. 2012. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196. [CrossRef]
303. Fuller LC. 2013. Epidemiology of scabies. Curr Opin Infect Dis 26:123–126. [PubMed][CrossRef]
304. Currie BJ, McCarthy JS. 2010. Permethrin and ivermectin for scabies. N Engl J Med 362:717–725. [PubMed][CrossRef]
305. Roberts LJ, Huffam SE, Walton SF, Currie BJ. 2005. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect 50:375–381. [PubMed][CrossRef]
306. Brook I. 1995. Microbiology of secondary bacterial infection in scabies lesions. J Clin Microbiol 33:2139–2140. [PubMed]
307. Blas M, Bravo F, Castillo W, Castillo WJ, Ballona R, Navarro P, Catacora J, Cairampoma R, Gotuzzo E. 2005. Norwegian scabies in Peru: the impact of human T cell lymphotropic virus type I infection. Am J Trop Med Hyg 72:855–857. [PubMed]
308. Bergman JN, Dodd WA, Trotter MJ, Oger JJ, Dutz JP. 1999. Crusted scabies in association with human T-cell lymphotropic virus 1. J Cutan Med Surg 3:148–152. [PubMed]
309. Prins C, Stucki L, French L, Saurat JH, Braun RP. 2004. Dermoscopy for the in vivo detection of Sarcoptes scabiei. Dermatology 208:241–243. [PubMed][CrossRef]
310. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 59(RR-12):1–110. [PubMed]
311. Garcia LS. 2009. Parasites, p 283–330. In Hayden RT, Carroll KC, Tang Y, Wolk DM (ed), Diagnostic Microbiology of the Immunocompromised Host. ASM Press, Washington, DC. [CrossRef]
312. Pritt BS. 2015. Plasmodium and Babesia, p In Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, Warnock DW (ed), Manual of Clinical Microbiology, vol 2. ASM Press, Washington, DC. [CrossRef]
microbiolspec.DMIH2-0013-2015.citations
cm/4/4
content/journal/microbiolspec/10.1128/microbiolspec.DMIH2-0013-2015
Loading

Citations loading...

Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.DMIH2-0013-2015
2016-08-12
2017-07-23

Abstract:

Parasites are an important cause of human disease worldwide. The clinical severity and outcome of parasitic disease is often dependent on the immune status of the host. Specific parasitic diseases discussed in this chapter are amebiasis, giardiasis, cryptosporidiosis, cyclosporiasis, cystoisosporiasis, microsporidosis, granulomatous amebic encephalitis, toxoplasmosis, leishmaniasis, Chagas disease, malaria, babesiosis, strongyloidiasis, and scabies.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Resected segment of colon showing multiple ulcers with focal perforation due to amebiasis. Amebic liver abscess with vial of aspirated abscess material demonstrating the characteristic “anchovy paste” appearance (Gross photos courtesy of Dr. Mae Melvin and Dr. E. West, CDC Public Health Image Library). / trophozoite (left) and cyst (right) (modified trichrome, 1000×). Reproduced with permission from Pritt BS. . Northfield, IL: College of American Pathologists, 2014. If ingested RBCs are seen within the cytoplasm of the trophozoite, then a presumptive diagnosis of can be made. Otherwise, the trophozoites and cysts of and are indistinguishable. Note that two of the four nuclei are visible within the cyst as well as a prominent chromatoid body.

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

trophozoites containing two nuclei, central axonemes and curved median bodies (left) and cyst with two of four nuclei visible (right) (trichrome stain, 1000×). Reproduced with permission from Pritt BS. . Northfield, IL: College of American Pathologists, 2014.

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Round oocysts of sp. stained with a modified acid-fast stain. Note that not all oocysts stain equally and that sporozoites can occasionally be seen within some oocysts (1000×).

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Round oocysts of stained using a modified acid-fast stain (1000×). They have a similar appearance to the oocysts of but are larger (8 to 10 µm in diameter). Note that not all oocysts stain uniformly, producing unstained “ghost” cells.

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

Immature oocyst of containing one sporocyst (modified acid-fast, 1000×). The oocysts are significantly larger than those of spp. and , measuring approximately 33 µm in length.

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 6
FIGURE 6

Microsporidial spores of in a concentrated fecal specimen demonstrating a characteristic band-like stripe (trichrome blue stain, 1000×). These tiny spores measure 0.8 to 1.4 µm in length and are therefore challenging to identify on standard microscopic preparations.

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 7
FIGURE 7

spp. trophozoites and cysts in a skin biopsy of an ulcerating skin lesion. Organisms are seen invading blood vessels in the dermis (left, H&E, 200×; arrow shows lumen of blood vessel). Higher magnification shows trophozoites with a small nucleus and large karyosome (top right) and cysts with a characteristic hexagonal double cell wall (bottom right) (H&E, 1000×).

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 8
FIGURE 8

Brain biopsy with multiple invading trophozoites; cysts are also commonly seen with both and infections but are not seen in this image.

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 9
FIGURE 9

. Free and intracellular arc-shaped tachyzoites in a brain impression smear (Giemsa, 1000×).

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 10
FIGURE 10

Characteristic ulcer of cutaneous leishmaniasis with proximal lymphatic spread (courtesy of Dr. Martins Castro and Dr. Lucille K. Georg, CDC PHIL). Air-dried impression smear from the edge of a cutaneous ulcer shows a macrophage containing numerous amastigotes (arrowhead denotes the macrophage nucleus, Giemsa, 1000×). A nucleus and rod-like kinetoplast can be seen within individual amastigotes (arrows).

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 11a
FIGURE 11a

trypomastigotes in a Giemsa-stained peripheral blood film. Note the characteristic large kinetoplast at the posterior end, central nucleus, and free flagellum at the anterior end (top, 1000×).

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 11b
FIGURE 11b

amastigotes in cardiac tissue (H&E, 400×, inset 1000×).

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 12
FIGURE 12

life cycle stages in the human host: early stage trophozoite (top left), late-stage trophozoite (top right), mature schizont (bottom left) and gametocyte (bottom right); (Giemsa, 1000×). Images from reference 312 .

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 13
FIGURE 13

Multiple parasite forms of MO1, showing pleomorphic intracellular forms, a characteristic “tetrad” form (arrowhead) and extracellular parasites (arrow) (Giemsa, 1000×). Image from reference 312 .

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 14
FIGURE 14

larvae invading the intestinal mucosa in a case of hyperinfection (H&E, 1000×).

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 15
FIGURE 15

mature mite (left), immature mite (bottom right) and egg (top right) in an unstained preparation of skin scrapings.

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015
Permissions and Reprints Request Permissions
Download as Powerpoint

Tables

Generic image for table
TABLE 1

Manifestation of parasitic infections in immunocompetent and immunocompromised hosts

Source: microbiolspec August 2016 vol. 4 no. 4 doi:10.1128/microbiolspec.DMIH2-0013-2015

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error